Bio-Techne Corporation
NASDAQ:TECHBiotechnology
-$1.03 today
- Market cap
- $11.43B
- Beta
- 1.36
- P/E (TTM)
- 78.3
- EPS (TTM)
- $0.70
- Dividend yield
- 0.58%
Volume 2.63M
Average 2.66M
TECH Interest Expense
Cost of servicing the company's debt during the period.
Bio-Techne CorporationNASDAQ: TECH
Interest Expense · Q1 FY2027 · quarter ended Sep 2026
Interest expense declines year over year
Q1 FY2027 interest expense of $2.17M fell 26.0% year over year, ahead of the -49.9% change in trailing-twelve-month interest expense. Over 3 fiscal years it compounded at -21.6% a year.
Context
- Interest expense amounted to 0.4% of revenue in FY2026, down 0.3 pp from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -26.0% holds above the trailing-twelve-month pace of -49.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2026
- 5.41M USD
- Year-over-year change
- -36.5%
- 4-year CAGR
- -16.9%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 5.41M | -36.5% |
| FY2025 | 2025-06-30 | 8.51M | -45.9% |
| FY2024 | 2024-06-30 | 15.74M | +40.3% |
| FY2023 | 2023-06-30 | 11.22M | -0.8% |
| FY2022 | 2022-06-30 | 11.31M | — |
Interest Expense vs competitors
How TECH compares with its peers on the latest reported figures
- TECH's LTM Sep 2026 interest expense of $4.64M is the 8th highest of the 11 companies compared; the peer median is $41.57M.
- Its year-over-year change of -49.9% is the 8th highest of 9, against a peer median of -15.7%.
- Interest expense amounts to 0.4% of revenue for TECH, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.54B | +6.9% | +25.0% | 3.2% | |
| LTM Sep 2026 | $146M | -46.1% | +8.6% | 0.6% | |
| LTM Jul 2026 | $106M | -9.4% | +10.1% | 1.4% | |
| LTM Jul 2026 | $93.99M | +1.0% | -3.9% | 3.2% | |
| LTM Jun 2026 | $43.7M | -22.0% | +55.3% | 1.2% | |
| LTM Jun 2026 | $39.43M | +5.1% | -17.1% | 1.9% | |
| LTM Jun 2026 | $36.7M | -25.0% | +8.7% | 1.4% | |
| LTM Sep 2026 | $4.64M | -49.9% | -21.6% | 0.4% | |
ALMRAlamar Biosciences, Inc. | FY2025 | $401K | — | — | 0.5% |
| LTM Sep 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TECH) | $41.57M | -15.7% | +8.7% | 1.3% | |
Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 1.11B | 1.14B | 1.16B | 1.22B | 1.22B |
| Cost of Revenue | 349.1M | 366.89M | 389.34M | 429.36M | 415.97M |
| Gross Profit | 756.5M | 769.82M | 769.73M | 790.27M | 799.07M |
| Gross Margin | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
| Research & Development | 87.14M | 92.49M | 96.66M | 99.5M | 94.77M |
| Selling, General & Admin | 339M | 352.44M | 393.32M | 415.1M | 452.42M |
| Operating Expenses | 459.91M | 470.87M | 563.04M | 688.02M | 547.18M |
| Depreciation & Amortization | 101.07M | 107.24M | 111.71M | 109.9M | 97.36M |
| EBITDA | 413.76M | 457.11M | 313.14M | 216.88M | 343.44M |
| EBITDA Margin | 37.4% | 40.2% | 27.0% | 17.8% | 28.3% |
| Operating Income | 296.59M | 298.94M | 206.69M | 102.26M | 251.89M |
| Operating Margin | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Interest Income | 794K | 3.41M | 3.32M | 3.89M | 0 |
| Interest Expense | 11.31M | 11.22M | 15.74M | 8.51M | 5.41M |
| Other Income / Expenses | 4.8M | 39.72M | (21M) | (3.79M) | (11.21M) |
| Income Before Tax | 301.39M | 338.66M | 185.69M | 98.46M | 240.68M |
| Pre-Tax Margin | 27.3% | 29.8% | 16.0% | 8.1% | 19.8% |
| Income Tax Expense | 38.29M | 53.22M | 17.58M | 25.06M | 58.82M |
| Net Income | 272.05M | 285.26M | 168.11M | 73.4M | 181.86M |
| Net Margin | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
| EPS (Basic) | 1.73 | 1.81 | 1.07 | 0.47 | 1.17 |
| EPS (Diluted) | 1.66 | 1.76 | 1.05 | 0.46 | 1.16 |
| Weighted Avg Shares | 156.88M | 157.18M | 157.71M | 157.52M | 155.96M |
| Weighted Avg Shares (Diluted) | 164.12M | 161.86M | 160.77M | 159.72M | 157.01M |
Bio-Techne Corporation
NASDAQ:TECH
Intrinsic Alpha fair value
Locked
Current Price
$72.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.